Skip to main content
SpringerLink
Log in

Comments on Economic Evaluation of Chemotherapy

  • Correspondence
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Williams C, Coyle D, Gray A, et al. European School of Oncology advisory report to the Commission of the European Communities for the ‘Europe against Cancer Programme’: cost-effectiveness in cancer care. Eur J Cancer 1995; 31(9): 1410–24

    Article  Google Scholar 

  2. Backhouse ME, Backhouse RJ, Edey SA. Economic evaluation bibliography. Health Econ 1992; 1 Suppl.: 1–235

    Google Scholar 

  3. Gerard K. Cost-utility in practice: a policy maker’s guide to the state of the art. Health Policy 1992; 21: 249–79

    Article  PubMed  CAS  Google Scholar 

  4. Elixhauser A, editor. Health care cost-benefit and cost-effectiveness analysis (CBA/CEA). From 1979 to 1990: a bibliography. Med Care 1993; 31 Suppl.: JS1–149

  5. Manson J, Drummond MF, Torrance G. Some guidelines on the use of cost-effectiveness league tables. BMJ 1993; 306: 570–2

    Article  Google Scholar 

  6. Drummond MF, Torrance G, Manson J. Cost-effectiveness league tables: more harm than good? Soc Sci Med 1993; 37: 33–40

    Article  PubMed  CAS  Google Scholar 

  7. Jønsson V, Clausen SR, Hansen MM. Pharmacoeconomic aspects in the treatment of curable and incurable cancer. Pharmacoeconomics 1995; 8(4): 275–281

    Article  PubMed  Google Scholar 

  8. National Board of Health, Denmark. Cancer treatment memorandum, Denmark [in Danish]. Copenhagen: Danish National Board Publishers, 1994

    Google Scholar 

  9. Jönsson B, Karlsson G. Economic evaluation of cancer treatments. In: Williams CJ, editor. Introducing new treatments for cancer: practical, ethical and legal problems. New York: John Wiley & Son, 1992: 237–65

    Google Scholar 

  10. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11(6): 1132–43

    PubMed  CAS  Google Scholar 

  11. Early Breast Cancer Trialist Collaborative group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1–15, 71-85

    Google Scholar 

  12. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1–6

    Article  PubMed  CAS  Google Scholar 

  13. Haller DG. An overview of adjuvant therapy for colorectal cancer. Eur J Cancer 1995; 31A: 1255–63

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharma Marketing Roche a/s, Industriholmen, Copenhagen, Denmark

    Simon R. Clausen

  2. Department of Haematology, Rigshospitalet University Hospital of Copenhagen, Copenhagen, Denmark

    Viggo Jønsson & Mogens M. Hansen

  3. Institute of Economics, University of Copenhagen, Copenhagen, Denmark

    Hans Keiding

  4. Department of Oncology, Aalborg Hospital, Aalborg, Denmark

    Mogens Kjær

  5. Department of Haematology, Odense University Hospital, Odense, Denmark

    Bjarne E. Christensen

  6. Department of Oncology, Rigshospitalet University Hospital of Copenhagen, Copenhagen, Denmark

    Henning Mouridsen

  7. Department of Oncology, Aarhus University Hospital, Aarhus, Denmark

    Torben Palshof

  8. Department of Oncology, Herlev University Hospital, Copenhagen, Denmark

    Steen W. Hansen

Authors
  1. Simon R. Clausen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Viggo Jønsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mogens M. Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hans Keiding
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mogens Kjær
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bjarne E. Christensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Henning Mouridsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Torben Palshof
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Steen W. Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clausen, S.R., Jønsson, V., Hansen, M.M. et al. Comments on Economic Evaluation of Chemotherapy. Pharmacoeconomics 12, 229–231 (1997). https://doi.org/10.2165/00019053-199712020-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199712020-00011

Keywords

Search

Navigation